调整 B 细胞淋巴瘤患者对 Polatuzumab Vedotin 的反应

IF 29.7 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2024-09-04 DOI:10.1158/2159-8290.CD-24-0644

Etienne Leveille, Shalin Kothari, Kadriye N Cosgun, Coraline Mlynarczyk, Markus Müschen

{"title":"调整 B 细胞淋巴瘤患者对 Polatuzumab Vedotin 的反应","authors":"Etienne Leveille, Shalin Kothari, Kadriye N Cosgun, Coraline Mlynarczyk, Markus Müschen","doi":"10.1158/2159-8290.CD-24-0644","DOIUrl":null,"url":null,"abstract":"Polatuzumab vedotin, an antibody-drug conjugate targeting CD79B, is the first new drug approved for first-line therapy of diffuse large B-cell lymphoma in more than two decades, although factors determining treatment responses to polatuzumab vedotin remain unknown. Two new studies identified central mechanisms of lower sensitivity, namely reduced accessibility of the CD79B epitope through N-linked glycosylation of CD79B and lower CD79B surface expression levels due to the activity of the KLHL6 E3 ligase. See related article by Corcoran et al., p. 1653 (6) See related article by Meriranta et al. (7).","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"14 9","pages":"1577-1580"},"PeriodicalIF":29.7000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma.\",\"authors\":\"Etienne Leveille, Shalin Kothari, Kadriye N Cosgun, Coraline Mlynarczyk, Markus Müschen\",\"doi\":\"10.1158/2159-8290.CD-24-0644\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Polatuzumab vedotin, an antibody-drug conjugate targeting CD79B, is the first new drug approved for first-line therapy of diffuse large B-cell lymphoma in more than two decades, although factors determining treatment responses to polatuzumab vedotin remain unknown. Two new studies identified central mechanisms of lower sensitivity, namely reduced accessibility of the CD79B epitope through N-linked glycosylation of CD79B and lower CD79B surface expression levels due to the activity of the KLHL6 E3 ligase. See related article by Corcoran et al., p. 1653 (6) See related article by Meriranta et al. (7).\",\"PeriodicalId\":9430,\"journal\":{\"name\":\"Cancer discovery\",\"volume\":\"14 9\",\"pages\":\"1577-1580\"},\"PeriodicalIF\":29.7000,\"publicationDate\":\"2024-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer discovery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/2159-8290.CD-24-0644\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/2159-8290.CD-24-0644","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Polatuzumab vedotin是一种靶向CD79B的抗体药物共轭物，是二十多年来首个获准用于弥漫大B细胞淋巴瘤一线治疗的新药，但决定对polatuzumab vedotin治疗反应的因素仍不清楚。两项新研究确定了降低敏感性的核心机制，即通过CD79B的N-连接糖基化降低CD79B表位的可及性，以及由于KLHL6 E3连接酶的活性降低CD79B表面表达水平。见 Corcoran 等人的相关文章，第 1653 页 (6) 见 Meriranta 等人的相关文章 (7)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma.

Polatuzumab vedotin, an antibody-drug conjugate targeting CD79B, is the first new drug approved for first-line therapy of diffuse large B-cell lymphoma in more than two decades, although factors determining treatment responses to polatuzumab vedotin remain unknown. Two new studies identified central mechanisms of lower sensitivity, namely reduced accessibility of the CD79B epitope through N-linked glycosylation of CD79B and lower CD79B surface expression levels due to the activity of the KLHL6 E3 ligase. See related article by Corcoran et al., p. 1653 (6) See related article by Meriranta et al. (7).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.